“Participation in a clinical trial is the first step in fighting cancer, not the last.” ®
A part of HCA Healthcare UK, Sarah Cannon Research Institute – UK provides access to cutting-edge therapies for patients in the community. As the first and only unit outside the NHS to offer new anti-cancer drugs in therapeutic clinical trials, Sarah Cannon Research Institute – UK serves both private and NHS patients. Through HCA Healthcare UK and Sarah Cannon, patients have access to the full cancer pathway across a number of specialist hospital and outpatient settings including dedicated private cancer facilities onsite at University College Hospital, The Christie and Guys and St Thomas’.
Sarah Cannon Research Institute is the research arm of HCA Healthcare’s global cancer institute, Sarah Cannon. For 25 years, the organisation has focused on advancing therapies for patients and has become one of the world’s leading clinical research organisations conducting community-based clinical trials throughout the United States and United Kingdom. The organisation has led more than 370 first-in-man clinical trials since its inception in 1993, and has been a clinical trial leader in the majority of approved cancer therapies over the last 10 years.
Sarah Cannon has many UK-based clinical trials in active enrolment providing patients with direct access to cutting-edge therapies at the earliest opportunity.
People who live with cancer – those who work to prevent it, fight it, and survive it – are at the heart of every decision we make. Bringing the most innovative medical minds together with the most passionate caregivers in their communities, we are transforming care and personalising treatment. Through clinical excellence and cutting-edge research, Sarah Cannon is redefining cancer care around the world.